Who is sponsoring NCT06760260?

NCT06760260 is sponsored by Hrain Biotechnology Co., Ltd..

What drugs are being tested in NCT06760260?

Interventions in NCT06760260: Human Derived anti-CI135 CAR-T Injection.

What condition does NCT06760260 study?

NCT06760260 studies Acute Myeloid Leukemia (AML).

Is NCT06760260 still recruiting?

NCT06760260 is currently recruiting now. Last updated 7 January 2025.

Last reviewed 2025-01-07 · How we verify

NCT06760260

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia

Recruiting now EARLY_PHASE1 Last updated 7 January 2025

What this trial tests

EARLY_PHASE1 trial testing Human Derived anti-CI135 CAR-T Injection in Acute Myeloid Leukemia (AML) in 7 participants. Currently enrolling.

Timeline

26 January 2022

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	Hrain Biotechnology Co., Ltd.
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	26 January 2022
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Human Derived anti-CI135 CAR-T Injection — full drug profile →

Conditions studied

Acute Myeloid Leukemia (AML) — all drugs for Acute Myeloid Leukemia (AML) →

Sponsor

Hrain Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 18 to 70, any sex, with Acute Myeloid Leukemia (AML). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory Acute Myeloid Leukemia.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation.
Zhao X, Ming X, Wu J, Zhu X, et al · · 2026 · cited 1× · PMID 41537901 · DOI 10.1007/s00277-026-06742-6
Co-Expression of IL-2 Enhances the Efficacy of FLT3-CAR-γδT Cells in Acute Myeloid Leukemia.
Wang X, You F, Gu Y, Ma X, et al · · 2026 · PMID 41899506 · DOI 10.3390/cancers18060901
Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.
Stafylidis C, Diamantopoulos PT. · · 2026 · PMID 41899095 · DOI 10.3390/jcm15062171

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia (AML)

Currently open trials in the same condition.

NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06707493 — Ivosidenib as Post-HSCT Maintenance for AML · Phase 2 · recruiting
NCT07458542 — Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia · active not recruiting

Other Hrain Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT06045091 — To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL · EARLY_PHASE1 · recruiting
NCT05651191 — To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL · EARLY_PHASE1 · unknown
NCT05651178 — Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients · EARLY_PHASE1 · recruiting
NCT05594797 — Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM · Phase 2 · recruiting
NCT05223686 — To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL. · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06760260 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hrain Biotechnology Co., Ltd.
Last refreshed: 7 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06760260.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing